Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dexcom Inc (DXCM)

Dexcom Inc (DXCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

DexCom's Q4 2025 Earnings: What to Expect

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $27.4 billion by market cap, the company develops a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin and a small external receiver to which the sensor transmits glucose levels at specified intervals. The global leader in glucose biosensing is expected to announce its fiscal fourth-quarter earnings for 2025 after the market closes on Thursday, Feb. 12.

Ahead of the event, analysts expect DXCM to report a profit of $0.65 per share on a...

Fundamentals

See More
  • Market Capitalization, $K 27,184,112
  • Shares Outstanding, K 390,016
  • Annual Sales, $ 4,033 M
  • Annual Income, $ 576,200 K
  • EBIT $ 778 M
  • EBITDA $ 995 M
  • 60-Month Beta 1.48
  • Price/Sales 6.25
  • Price/Cash Flow 31.26
  • Price/Book 10.05

Options Overview Details

View History
  • Implied Volatility 56.72% (-0.05%)
  • Historical Volatility 25.80%
  • IV Percentile 83%
  • IV Rank 58.13%
  • IV High 77.57% on 10/30/25
  • IV Low 27.78% on 08/05/25
  • Expected Move (DTE 7) 2.37 (3.43%)
  • Put/Call Vol Ratio 3.70
  • Today's Volume 8,753
  • Volume Avg (30-Day) 5,086
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 193,750
  • Open Int (30-Day) 187,227
  • Expected Range 66.87 to 71.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.65
  • Number of Estimates 11
  • High Estimate 0.69
  • Low Estimate 0.59
  • Prior Year 0.45
  • Growth Rate Est. (year over year) +44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.19 +6.21%
on 01/05/26
72.50 -4.50%
on 01/12/26
+3.51 (+5.34%)
since 12/15/25
3-Month
54.11 +27.96%
on 11/07/25
72.50 -4.50%
on 01/12/26
+3.83 (+5.86%)
since 10/15/25
52-Week
54.11 +27.96%
on 11/07/25
93.25 -25.75%
on 02/18/25
-11.16 (-13.88%)
since 01/15/25

Most Recent Stories

More News
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

DXCM : 69.24 (-0.66%)
DexCom's Q4 2025 Earnings: What to Expect

DexCom will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

XLV : 156.96 (-0.57%)
$SPX : 6,944.47 (+0.26%)
DXCM : 69.24 (-0.66%)
S&P Futures Muted as Investors Weigh JPMorgan Earnings, U.S. Inflation Data in Focus

March S&P 500 E-Mini futures (ESH26) are trending down -0.08% this morning as investors digest an earnings report from JPMorgan Chase, the nation’s largest bank by assets, with the focus now turning...

SYF : 77.70 (-0.15%)
ORSTE.C.DX : 132.750 (+1.34%)
JPM : 309.26 (+0.45%)
SIKA.Z.EB : 150.800 (-2.57%)
ESH26 : 7,000.00 (+0.26%)
STX : 320.32 (+2.57%)
INTC : 48.32 (-0.82%)
WDC : 222.10 (+3.30%)
SNPS : 508.19 (+0.56%)
AMD : 227.92 (+1.93%)
UPS : 108.62 (+1.14%)
COF : 236.97 (+1.09%)
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the...

DXCM : 69.24 (-0.66%)
DexCom (DXCM) Stock Trades Down, Here Is Why

DexCom (DXCM) Stock Trades Down, Here Is Why

DXCM : 69.24 (-0.66%)
Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer

Mr. Leach begins his inaugural year as CEO with speaking engagements at CES 2026 and the 44 th annual J.P. Morgan Healthcare Conference A completely reimagined...

DXCM : 69.24 (-0.66%)
3 Nasdaq 100 Stocks Worth Your Attention

3 Nasdaq 100 Stocks Worth Your Attention

META : 620.80 (+0.86%)
ORLY : 93.64 (-1.45%)
DXCM : 69.24 (-0.66%)
2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

LNTH : 65.42 (-0.27%)
DXCM : 69.24 (-0.66%)
BMY : 56.62 (-0.70%)
DexCom, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights - DXCM

NEW YORK , Dec. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.

DXCM : 69.24 (-0.66%)
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

DXCM : 69.24 (-0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of...

See More

Key Turning Points

3rd Resistance Point 70.96
2nd Resistance Point 70.51
1st Resistance Point 69.87
Last Price 69.24
1st Support Level 68.79
2nd Support Level 68.34
3rd Support Level 67.70

See More

52-Week High 93.25
Fibonacci 61.8% 78.30
Fibonacci 50% 73.68
Last Price 69.24
Fibonacci 38.2% 69.06
52-Week Low 54.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar